Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma
Keyword(s):
Phase I
◽
2016 ◽
Vol 34
(15_suppl)
◽
pp. e13518-e13518
2010 ◽
Vol 103
(2)
◽
pp. 325-332
◽
2007 ◽
Vol 69
(3)
◽
pp. 825-830
◽
2011 ◽
Vol 81
(2)
◽
pp. 468-475
◽
2011 ◽
Vol 81
(4)
◽
pp. 1066-1074
◽